Evidence map›Paper›PMID 37743074›Full record

ReviewCardiology clinics2023

Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?

Jiun-Ruey Hu, Alexandra N Schwann, Jia Wei Tan, Abdulelah Nuqali, Ralph J Riello, Michael H Beasley

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiology clinics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jiun-Ruey HuClinical and Translational Research Accelerator, Yale School of Medicine, New Haven, CT 06520, USA. Electronic address: https://twitter.com/ruey_hu.
Alexandra N SchwannDepartment of Internal Medicine, Yale New Haven Hospital, P.O. Box 208030, New Haven, CT, 06520-8030, USA. Electronic address: https://twitter.com/aschwann212.
Jia Wei TanDivision of Nephrology, Stanford University School of Medicine, 780 Welch Road, Palo Alto, CA 94304, USA. Electronic address: https://twitter.com/jiiiiawei.
Abdulelah NuqaliClinical and Translational Research Accelerator, Yale School of Medicine, New Haven, CT 06520, USA. Electronic address: https://twitter.com/AbdulelahNuqali.
Ralph J RielloClinical and Translational Research Accelerator, Yale School of Medicine, New Haven, CT 06520, USA. Electronic address: https://twitter.com/ralphadelta.
Michael H BeasleyClinical and Translational Research Accelerator, Yale School of Medicine, New Haven, CT 06520, USA. Electronic address: michael.beasley@yale.edu.
Yale University · USStanford University · USYale New Haven Hospital · US

Funding

POSTDOCTORAL TRAINING IN MEDICAL INFORMATION SCIENCEST15LM007033 · NLM · STANFORD UNIVERSITY · PI SYLVIA KATINA PLEVRITIS · 1985 to 2026
$25.5M
NLM NIH HHS T15 LM007033
6 · The paper itself

Abstract

The conventional sequence of guideline-directed medical therapy (GDMT) initiation in heart failure with reduced ejection fraction (HFrEF) assumes that the effectiveness and tolerability of GDMT agents mirror their order of discovery, which is not true. In this review, the authors discuss flexible GDMT sequencing that should be permitted in special populations, such as patients with bradycardia, chronic kidney disease, or atrial fibrillation. Moreover, the initiation of certain GDMT medications may enable tolerance of other GDMT medications. Most importantly, the achievement of partial doses of all four pillars of GDMT is better than achievement of target dosing of only a couple.

Indexed as

Heart FailureAtrial FibrillationDrug ToleranceHumansRenal Insufficiency, ChronicStroke VolumeBeta blockersGuideline-directed medical therapyHeart failure with reduced ejection fractionMineralocorticoid receptor antagonistsRenin–angiotensin aldosterone system inhibitorsSequenceSodium–glucose cotransporter 2 inhibitorsTolerability

Identifiers

PMID37743074
PMCPMC12070421
OpenAlexW4386958208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.